Advances in Treating Relapsed Diffuse Large B Cell Lymphoma Treatment Volume 4 - Issue 4

Dahlia Sano*

• Department of Oncology, Karmanos Cancer Institute, Wayne State University, USA

Received:April 19, 2021   Published: May 13, 2021

Corresponding author: Department of Oncology, Karmanos Cancer Institute, Wayne State University, USA

DOI: 10.32474/OAJOM.2021.04.000192

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), comprising about 25% of all mature NHL. First-line therapy cures about 40-60% of patients. High dose chemotherapy followed by autologous stem cell transplant can cure about 50% of patients at relapse. Transplant-ineligible patients have shorter survival with every line of subsequent therapies with a median overall survival (OS) of 10 months at second line and 4.7 months at fourth lines of therapy. There is unmet need to treat patients with relapsed DLBCL. Chimeric antigen receptor T-Cells (CAR-T), with now three FDA- approved products to treat relapsed DLBCL, provide a cure in about 40% of patients. Other recently approved agents include antibody-drug conjugate targeting CD79b (Polatuzumab Vedotin), Anti-CD19 antibodies (Tafasitamab-cxix), and nuclear export inhibitor XPO1 (Selinexor) have provided a hope to patients with relapsed DLBCL. We will discuss these new approvals with comparison of response rate and side effect profiles.

Keywords: Diffuse Large B Cell Lymphoma; CAR-T Cell Therapy; Tafasitamab; Relapsed Refractory Lymphoma; Polatuzumab

Abstract| Introduction| Conclusion and opinion| References|